Limits...
Hyperuricemia and incident cardiovascular disease and noncardiac vascular events in patients with rheumatoid arthritis.

Kuo D, Crowson CS, Gabriel SE, Matteson EL - Int J Rheumatol (2014)

Bottom Line: A population-based inception cohort of patients diagnosed between 1980 and 2007 with adult-onset RA was assembled.A comparison cohort of age- and sex-matched subjects without RA (non-RA) was also assembled.Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA.

ABSTRACT
Objective. To evaluate whether hyperuricemia is a risk factor for cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). Methods. A population-based inception cohort of patients diagnosed between 1980 and 2007 with adult-onset RA was assembled. A comparison cohort of age- and sex-matched subjects without RA (non-RA) was also assembled. All clinically obtained uric acid values were collected. CVD and noncardiac vascular events were recorded for each patient. Cox proportional hazards models were used to assess the impact of hyperuricemia on development of CVD, mortality, and noncardiac vascular disease. Results. In patients without RA, hyperuricemia was associated with heart failure (HR: 1.95; 95% CI: 1.13-3.39) and CVD (HR: 1.59; 95% CI: 0.99-2.55). In patients with RA, hyperuricemia was not significantly associated with CVD but was significantly associated with peripheral arterial events (HR: 2.52; 95% CI: 1.17-5.42). Hyperuricemia appeared to be more strongly associated with mortality among RA patients (HR: 1.96; 95% CI: 1.45-2.65) than among the non-RA subjects (HR: 1.57; 95% CI: 1.09-2.24). Conclusion. In patients with RA, hyperuricemia was a significant predictor of peripheral arterial events and mortality but not of CVD.

No MeSH data available.


Related in: MedlinePlus

Trends in serum uric acid over time in patients with rheumatoid arthritis (RA; solid line) and without RA (dashed line).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4150464&req=5

fig1: Trends in serum uric acid over time in patients with rheumatoid arthritis (RA; solid line) and without RA (dashed line).

Mentions: There were no apparent assay changes in SUA ranges by calendar years of interest (figure not shown). Examination of trends in serum uric acid according to time since RA incidence/index date revealed that the average serum uric acid decreases in RA patients prior to diagnosis of RA (Figure 1). SUA remains lower in RA on average than in non-RA for the first 10 years of RA disease duration.


Hyperuricemia and incident cardiovascular disease and noncardiac vascular events in patients with rheumatoid arthritis.

Kuo D, Crowson CS, Gabriel SE, Matteson EL - Int J Rheumatol (2014)

Trends in serum uric acid over time in patients with rheumatoid arthritis (RA; solid line) and without RA (dashed line).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4150464&req=5

fig1: Trends in serum uric acid over time in patients with rheumatoid arthritis (RA; solid line) and without RA (dashed line).
Mentions: There were no apparent assay changes in SUA ranges by calendar years of interest (figure not shown). Examination of trends in serum uric acid according to time since RA incidence/index date revealed that the average serum uric acid decreases in RA patients prior to diagnosis of RA (Figure 1). SUA remains lower in RA on average than in non-RA for the first 10 years of RA disease duration.

Bottom Line: A population-based inception cohort of patients diagnosed between 1980 and 2007 with adult-onset RA was assembled.A comparison cohort of age- and sex-matched subjects without RA (non-RA) was also assembled.Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA.

ABSTRACT
Objective. To evaluate whether hyperuricemia is a risk factor for cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). Methods. A population-based inception cohort of patients diagnosed between 1980 and 2007 with adult-onset RA was assembled. A comparison cohort of age- and sex-matched subjects without RA (non-RA) was also assembled. All clinically obtained uric acid values were collected. CVD and noncardiac vascular events were recorded for each patient. Cox proportional hazards models were used to assess the impact of hyperuricemia on development of CVD, mortality, and noncardiac vascular disease. Results. In patients without RA, hyperuricemia was associated with heart failure (HR: 1.95; 95% CI: 1.13-3.39) and CVD (HR: 1.59; 95% CI: 0.99-2.55). In patients with RA, hyperuricemia was not significantly associated with CVD but was significantly associated with peripheral arterial events (HR: 2.52; 95% CI: 1.17-5.42). Hyperuricemia appeared to be more strongly associated with mortality among RA patients (HR: 1.96; 95% CI: 1.45-2.65) than among the non-RA subjects (HR: 1.57; 95% CI: 1.09-2.24). Conclusion. In patients with RA, hyperuricemia was a significant predictor of peripheral arterial events and mortality but not of CVD.

No MeSH data available.


Related in: MedlinePlus